Item 2.02. Results of Operations and Financial Condition.

On September 23, 2021, Applied Genetic Technologies Corporation (the "Company") issued a press release entitled "AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021." A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01. Regulation FD Disclosure.

During its earnings call on September 23, 2021, the Company will present a summary of recent corporate and clinical developments. A copy of the slide presentation that will be used by officers of the Company in connection with the earnings call (the "Corporate Presentation") is attached to this Current Report on Form 8-K as Exhibit 99.2. The Corporate Presentation is current as of September 23, 2021, and the Company disclaims any obligation to correct or update this material in the future.

The information in the press release attached hereto as Exhibit 99.1 and the Corporate Presentation attached hereto as Exhibit 99.2 are intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



Exhibit No.       Description

99.1                Press release issued on September 23, 2021 entitled "AGTC
                  Provides Financial Results for the Fourth Quarter and Year Ended
                  June 30, 2021"

99.2                Corporate Presentation current as of September 23, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses